Skip to main content
. 2023 Sep 22;9(38):eadg1391. doi: 10.1126/sciadv.adg1391

Table 1. Characteristics of study participants from the MoBa and Senior cohort, by menopausal status.

IQR, inter quartile range.

Postmenopausal women (n = 7725) Perimenopausal women (n = 7148) Premenopausal, nonmenstruating (n = 7052)
Cohort
 MoBa*, n (%) 5710 (73.9) 7148 (100) 7052 (100)
 Senior cohort, n (%) 2015 (26.1) 0 0
Age groups, n (%)
 <35 0 0 13 (0.2)
 35–39 4 (0.1) 13 (0.2) 335 (4.8)
 40–44 43 (0.6) 150 (2.1) 1953 (27.7)
 45–49 380 (4.9) 1593 (22.3) 3417 (48.5)
 50–54 2299 (29.8) 4380 (61.3) 1254 (17.8)
 55–59 2550 (33.0) 998 (14.0) 70 (1.0)
 60–64 434 (5.6) 14 (0.2) 10 (0.1)
 65–69 653 (8.5) 0 0
 70–74 740 (9.6) 0 0
 75–79 528 (6.8) 0 0
 ≥ 80 94 (1.2) 0 0
Age, median 56 52 45
Fill in date, median (min, max) 2 Sep (20 Aug, 19 Oct) 1 Sep (20 Aug, 16 Sep) 1 Sep (20 Aug, 16 Sep)
COVID-19 vaccination status
Dose 1, n (%) 7574 (98.0) 7016 (98.2) 6941 (98.4)
Date dose 1, median (IQR) 12 May (2 Apr–17 Jun) 16 Jun (5 May–24 Jun) 21 Jun (30 Apr–1 Jul)
Interval in days (dose 1–dose 2), median (IQR) 42 (42–57) 49 (42–61) 44 (41–57)
 Vaxzevria (AstraZenaca), n (%) 449 (5.9) 554 (7.9) 653 (9.4)
 Comirnaty (Pfizer-BioNTech), n (%) 5860 (77.4) 5538 (78.9) 5482 (79.0)
 Spikevax (Moderna), n (%) 1263 (16.7) 923 (13.2) 806 (11.6)
 Other, n (%) 2 (<0.1) 1 (<0.1) 0
Dose 2, n (%) 7337 (95.0) 6669 (93.3) 6450 (91.5)
Date dose 2, median (IQR) 18 Jun (19 May–12 Aug) 8 Aug (16 Jun–18 Aug) 9 Aug (9 Jun–19 Aug)
Interval in days (dose 2–fill in date), median (IQR) 75 (21–125) 26 (14–78) 25 (13–84)
 Vaxzevria (AstraZeneca), n (%) 0 2 (<0.1) 0
 Comirnaty (Pfizer-BioNTech), n (%) 5847 (76.2) 5016 (75.2) 4883 (75.7)
 Spikevax (Moderna), n (%) 1750 (23.9) 1650 (24.7) 1567 (24.3)
 Other, n (%) 0 1 (<0.1) 0
Hormone/contraception use, n (%)
 Yes§ 2044 (26.5) 4089 (57.2) 6030 (85.5)
 No 5681 (73.5) 3059 (42.8) 1022 (14.5)
Any gynecological condition, n (%)
 Yes║ 1247 (16.1) 1379 (19.3) 1020 (14.5)
 No 6193 (80.2) 5441 (76.1) 5843 (82.9)
 Do not know, n (%) 285 (3.7) 328 (4.6) 189 (2.7)

*MoBa participants.

†Senior cohort participants.

‡All dates are in 2021.

§Women who reported use of combination pill, progestin-only pill, IUD (hormonal), IUD (copper), contraceptive implant, other contraception, HRT, and other hormone treatment (details are presented in table S1).

║Women who reported to have had myomas/adenomyosis, endometriosis, polycystic ovary syndrome, cervical cancer, endometrial cancer, or “other gynecological condition” (details are presented in table S1).

¶Women answered “No” to all abovementioned items.